According to MedCity News, Interra Health is helping Medicare patients access GLP-1 drugs through the Bridge program at $50 per month. The company's move is framed as added support for the program, though the report does not describe exactly what that support involves.
Because there is only one source, there are no independent accounts to compare. The report confirms the program's price point and Medicare focus, but leaves open questions about eligibility, which GLP-1 drugs are covered, and how Interra Health's role works in practice.